http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2560686-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3448362b85c951056cfe8e1e473b2cf0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32568c9063dae238b4c702634d72a512
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-72
filingDate 2014-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cee830e6636094485776e218e517a77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f07ca4f38465580c545913b38956efca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fa127ea36f62788961199c8711e144b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfedd1d7885863982a378b9c3c661b1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4b03d031e379414234c6c9892ef60ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faa3e341c6dc17b191cfbcefcb133ecb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32a03c414afd18b0e8c0f230366c74bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bf1f337796cacf8fc45836c75dacc4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22e251727f0e4bec49ffecedb62fadb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3d1fb06c5847e47eea75184fb7041ee
publicationDate 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2560686-C2
titleOfInvention Pharmaceutical composition for treating herpetic infections
abstract FIELD: medicine. n SUBSTANCE: as active agents, the composition contains triazavirin in an amount of 1.5-2.0 wt % and sea buckthorn oil in an amount of 1.5 - 2.0 wt %, whereas a gel base represents silicone glycerohydrogel Si(C 3 H 7 O 3 ) 4 ·6C 3 H 8 O 3 ·24H 2 O. n EFFECT: invention has high therapeutic activity and an increased rate of pathological element epithelisation alongside with no adverse side effect. n 5 ex
priorityDate 2014-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2178693-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2294936-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2326667-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2255939-C2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO77811
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO77698
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ29477
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398513
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCK9IMD0
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID515951
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP08071
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9TUM0
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID379502
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID193516
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP02788
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP14632
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474481
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP24627
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555458
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID17002
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID280846
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID398723
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID193516
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID613079
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445638

Total number of triples: 50.